Clinical efficacy and tolerance of 1% nadifloxacin cream in the treatment of mild to moderate acne vulgaris in South Korea

Won Jun Choi, Kwang Joong Kim, Nack In Kim, Young Chul Kye, Dae Hun Suh, Joo Heung Lee, Myeung Nam Kim, Eun So Lee, Ju Hee Lee, Young Suck Ro

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Antimicrobials have been a mainstay of inflammatory acne treatment for more than 30 years. However, antibiotic-resistant propionibacteria had been isolated with increased frequency, and associated with failure to respond to antibiotic therapy. Objective: The aim of this study was to investigate the clinical efficacy and tolerance of 1% nadifloxacin cream. Methods: In the final analysis, 197 patients with mild to moderate facial acne vulgaris were enrolled. The patients were instructed to apply 1% nadifloxacin cream twice daily to the affected skin after washing the face. Following 2 and 4 weeks of treatment, patients were observed for clinical response: number of the acne lesions, Korea acne grading system (KAGS), global improvement, and occurrence of adverse reactions. Results: During 4 weeks of treatment, nadifloxacin caused significant reduction in the number of inflamed papulo-pustular lesions and open/closed comedones. In addition, significant reduction of KAGS was observed. About 96% of patients showed clinical improvement in the overall evaluation of the therapeutic effect by physicians. All reported adverse events were mild. Conclusion: This study shows that 1% nadifloxacin cream can be an effective and safe treatment for mild to moderate acne vulgaris.

Original languageEnglish
Pages (from-to)665-671
Number of pages7
JournalKorean Journal of Dermatology
Volume48
Issue number8
Publication statusPublished - 2010 Aug 1

Fingerprint

nadifloxacin
Republic of Korea
Acne Vulgaris
Korea
Therapeutics
Propionibacterium
Anti-Bacterial Agents
Therapeutic Uses

Keywords

  • 1% nadifloxacin cream
  • Acne
  • Treatment

ASJC Scopus subject areas

  • Dermatology

Cite this

Clinical efficacy and tolerance of 1% nadifloxacin cream in the treatment of mild to moderate acne vulgaris in South Korea. / Choi, Won Jun; Kim, Kwang Joong; Kim, Nack In; Kye, Young Chul; Suh, Dae Hun; Lee, Joo Heung; Kim, Myeung Nam; Lee, Eun So; Lee, Ju Hee; Ro, Young Suck.

In: Korean Journal of Dermatology, Vol. 48, No. 8, 01.08.2010, p. 665-671.

Research output: Contribution to journalArticle

Choi, WJ, Kim, KJ, Kim, NI, Kye, YC, Suh, DH, Lee, JH, Kim, MN, Lee, ES, Lee, JH & Ro, YS 2010, 'Clinical efficacy and tolerance of 1% nadifloxacin cream in the treatment of mild to moderate acne vulgaris in South Korea', Korean Journal of Dermatology, vol. 48, no. 8, pp. 665-671.
Choi, Won Jun ; Kim, Kwang Joong ; Kim, Nack In ; Kye, Young Chul ; Suh, Dae Hun ; Lee, Joo Heung ; Kim, Myeung Nam ; Lee, Eun So ; Lee, Ju Hee ; Ro, Young Suck. / Clinical efficacy and tolerance of 1% nadifloxacin cream in the treatment of mild to moderate acne vulgaris in South Korea. In: Korean Journal of Dermatology. 2010 ; Vol. 48, No. 8. pp. 665-671.
@article{1682648544ae425c9d0f2b27f4842b90,
title = "Clinical efficacy and tolerance of 1{\%} nadifloxacin cream in the treatment of mild to moderate acne vulgaris in South Korea",
abstract = "Background: Antimicrobials have been a mainstay of inflammatory acne treatment for more than 30 years. However, antibiotic-resistant propionibacteria had been isolated with increased frequency, and associated with failure to respond to antibiotic therapy. Objective: The aim of this study was to investigate the clinical efficacy and tolerance of 1{\%} nadifloxacin cream. Methods: In the final analysis, 197 patients with mild to moderate facial acne vulgaris were enrolled. The patients were instructed to apply 1{\%} nadifloxacin cream twice daily to the affected skin after washing the face. Following 2 and 4 weeks of treatment, patients were observed for clinical response: number of the acne lesions, Korea acne grading system (KAGS), global improvement, and occurrence of adverse reactions. Results: During 4 weeks of treatment, nadifloxacin caused significant reduction in the number of inflamed papulo-pustular lesions and open/closed comedones. In addition, significant reduction of KAGS was observed. About 96{\%} of patients showed clinical improvement in the overall evaluation of the therapeutic effect by physicians. All reported adverse events were mild. Conclusion: This study shows that 1{\%} nadifloxacin cream can be an effective and safe treatment for mild to moderate acne vulgaris.",
keywords = "1{\%} nadifloxacin cream, Acne, Treatment",
author = "Choi, {Won Jun} and Kim, {Kwang Joong} and Kim, {Nack In} and Kye, {Young Chul} and Suh, {Dae Hun} and Lee, {Joo Heung} and Kim, {Myeung Nam} and Lee, {Eun So} and Lee, {Ju Hee} and Ro, {Young Suck}",
year = "2010",
month = "8",
day = "1",
language = "English",
volume = "48",
pages = "665--671",
journal = "Korean Journal of Dermatology",
issn = "0494-4739",
publisher = "Korean Dermatological Association",
number = "8",

}

TY - JOUR

T1 - Clinical efficacy and tolerance of 1% nadifloxacin cream in the treatment of mild to moderate acne vulgaris in South Korea

AU - Choi, Won Jun

AU - Kim, Kwang Joong

AU - Kim, Nack In

AU - Kye, Young Chul

AU - Suh, Dae Hun

AU - Lee, Joo Heung

AU - Kim, Myeung Nam

AU - Lee, Eun So

AU - Lee, Ju Hee

AU - Ro, Young Suck

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Background: Antimicrobials have been a mainstay of inflammatory acne treatment for more than 30 years. However, antibiotic-resistant propionibacteria had been isolated with increased frequency, and associated with failure to respond to antibiotic therapy. Objective: The aim of this study was to investigate the clinical efficacy and tolerance of 1% nadifloxacin cream. Methods: In the final analysis, 197 patients with mild to moderate facial acne vulgaris were enrolled. The patients were instructed to apply 1% nadifloxacin cream twice daily to the affected skin after washing the face. Following 2 and 4 weeks of treatment, patients were observed for clinical response: number of the acne lesions, Korea acne grading system (KAGS), global improvement, and occurrence of adverse reactions. Results: During 4 weeks of treatment, nadifloxacin caused significant reduction in the number of inflamed papulo-pustular lesions and open/closed comedones. In addition, significant reduction of KAGS was observed. About 96% of patients showed clinical improvement in the overall evaluation of the therapeutic effect by physicians. All reported adverse events were mild. Conclusion: This study shows that 1% nadifloxacin cream can be an effective and safe treatment for mild to moderate acne vulgaris.

AB - Background: Antimicrobials have been a mainstay of inflammatory acne treatment for more than 30 years. However, antibiotic-resistant propionibacteria had been isolated with increased frequency, and associated with failure to respond to antibiotic therapy. Objective: The aim of this study was to investigate the clinical efficacy and tolerance of 1% nadifloxacin cream. Methods: In the final analysis, 197 patients with mild to moderate facial acne vulgaris were enrolled. The patients were instructed to apply 1% nadifloxacin cream twice daily to the affected skin after washing the face. Following 2 and 4 weeks of treatment, patients were observed for clinical response: number of the acne lesions, Korea acne grading system (KAGS), global improvement, and occurrence of adverse reactions. Results: During 4 weeks of treatment, nadifloxacin caused significant reduction in the number of inflamed papulo-pustular lesions and open/closed comedones. In addition, significant reduction of KAGS was observed. About 96% of patients showed clinical improvement in the overall evaluation of the therapeutic effect by physicians. All reported adverse events were mild. Conclusion: This study shows that 1% nadifloxacin cream can be an effective and safe treatment for mild to moderate acne vulgaris.

KW - 1% nadifloxacin cream

KW - Acne

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=79960902781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960902781&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79960902781

VL - 48

SP - 665

EP - 671

JO - Korean Journal of Dermatology

JF - Korean Journal of Dermatology

SN - 0494-4739

IS - 8

ER -